5Green S Watanade K, Braatz-Trulon J. Inhition of dihydroorotate dehydrogrogenase by the immunosuppressine agent leflunnomide[J]. Biochem pharmacol, 1995, 50(6): 861.
6Siemasko K F, Chong A S, Willams J W, et al. Regulation of Bcellfunction by the immunosuppressive agentleflunomide[J]. Transplantation, 1996, 61(4): 635.
7Mana S K, Aggarwall B B. Immunosuppressive leflunnomide metabolite(A771726) blocks TNF-dependent nuelfactor-Kappa B activation and gene expression[J]. J Immunol, 1999, 162(4): 2095.
8Francois Mach, Myit S Kwak B, Multhaupt F, et al.Statins asnewly recognized type of immunmodulator[J]. Nature, 2000, 6: 1399.
9Menge T, Hartung H P, Stave O. Statins-a cure-all for the brain[J]. Nat Rev, 2005, 6:325.
8[1]Usui H,Shikata K,Matsuda M,et al.HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats[J].Nephrol Dial Transplant,2003,18(2):265-272.
9[2]Ota T,Takamura T,Ando H,et al.Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model[J].Diabetologia,2003,46(6):843-851.
10[3]Nogaki F,Muso E,Yashiro M,et al.Direct inhibitory effects of simvastatin on matrix accumulation in cultured murine mesangial cells[J].Kidney Int Suppl,1999,71:S198-201.
6Koneru S, Kocharla L, Higgins GC, et al. Adherence to medications in systemic lupus erythematosus [J]. Clin Rheumatol, 2008, 14 (4): 195-201.
7Ogawa H, Kameda H, Nagasawa H, et al. Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis [J]. Mod Rheumatol, 2007, 17(2): 92-108.
8Silva-FemdezL, Andreu-Schez JL, Ginzler EM. Current therapy of lu- pus nephritis -Which is the best option? [J]. Rev Clin Esp,2008, 208 (3): 138-141.
10Moore RA, Derry S. Systematic review and mete-analysis of randomized trials and cohort studies of mycophenolate mofetil in lupus nephritis[J]. Arthritis Res Ther, 2006, 8(6): 182.
